in Two Phase 2a Clinical Trials with Broad-Spectrum Influenza Vaccine Candidate OVX836.
Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, today announced the Last Patient Last Visit (LPLV) in two Phase 2a clinical trials evaluating Osivax’ lead T-cell based, broad-spectrum influenza vaccine candidate, OVX836. OVX836 has been developed using the company’s proprietary oligoDOM® nanoparticle technology platform and is designed to produce immune responses against the nucleoprotein (NP), an internal antigen highly conserved across flu strains. The LPLVs were completed in: a dose-optimization study (OVX836-003) underway in Belgium, extended to include elderly participants aged 65 years and older, and a co-administration study being conducted in Australia (OVX836-004) with OVX836 and a quadrivalent inactivated influenza virus (QIV) vaccine. Topline results from both studies are anticipated in the first half of 2023.